Koyfin Home > Directory > Health Care > Adma Biologics > EBITDA Margin

Adma Biologics EBITDA Margin Chart (ADMA)

Adma Biologics annual/quarterly EBITDA Margin from 2011 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Adma Biologics EBITDA Margin for the quarter ending June 06, 2020 was $-209m a 45.34% decrease of -95m year over year
  • Adma Biologics EBITDA Margin for the last 12 months ending June 06, 2020 was $-127m a -74.10% increase of 94m year over year
  • Adma Biologics Annual EBITDA Margin for 2019 was $-130m a -157.35% increase of 205m from 2018
  • Adma Biologics Annual EBITDA Margin for 2018 was $-335m a 26.30% decrease of -88m from 2017
  • Adma Biologics Annual EBITDA Margin for 2017 was $-247m a 35.88% decrease of -88m from 2016
Other Margins & Efficiency Metrics:
  • Adma Biologics Return on Capital % for the quarter ending September 09, 2018 was -40.32 a 8.20% decrease of -3.30 year over year
  • Adma Biologics Return on Equity % for the quarter ending September 09, 2018 was -136.10 a -43.11% increase of 58.67 year over year
View Chart On Koyfin

Quarterly ADMA EBITDA Margin Data

06/2020$-209m
03/2020$-157m
12/2019$-58m
09/2019$-114m
06/2019$-161m
03/2019$-352m
12/2018$-385m
09/2018$-306m
06/2018$-270m
03/2018$-388m

Annual ADMA EBITDA Margin Data

2019$-130m
2018$-335m
2017$-247m
2016$-158m
2015$-210m
2014$-267m
2013$-484m
2012$-691m
2011$-324m